Johnson & Johnson and Omrix Biopharmaceuticals, Inc, a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting through Ethicon, Inc, a Johnson & Johnson company and leading provider of suture, mesh, hemostats and other products for a wide range of surgical procedures.
The details can be read here.
No comments:
Post a Comment